title: Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.
abstract: OBJECTIVE
  To investigate the efficacy and safety of amiodarone administered as the drug of first choice in the conversion of atrial fibrillation, regardless of its duration.
  
  
  METHODS
  : Prospective, randomized, controlled clinical study.
  
  
  METHODS
  : Tertiary cardiac referral center.
  
  
  METHODS
  Two-hundred eight consecutive patients (102 men; mean [+/- SD] age, 65 +/- 10 years) with atrial fibrillation.
  
  
  METHODS
  One-hundred eight patients received amiodarone, and 100 patients received placebo treatment. Patients randomized to amiodarone received 300 mg IV for 1 h, and then 20 mg/kg for 24 h. They were also given 600 mg/d orally, divided into three doses, for 1 week, and thereafter 400 mg/d for 3 weeks. Patients randomized to placebo treatment received an identical amount of saline solution IV over 24 h, and oral placebo treatment for 1 month.
  
  
  RESULTS
  Baseline clinical characteristics were similar in the two groups. Conversion to sinus rhythm was achieved in 87 of 108 patients (80.05%) who received amiodarone, and in 40 of 100 patients (40%) in the placebo group (p < 0.0001). Statistical analysis showed that the duration of the arrhythmia and the size of the left atrium affected both the likelihood of conversion to sinus rhythm and the time to conversion in both groups. No side effects requiring discontinuation of treatment were observed in either group.
  
  
  CONCLUSIONS
  Amiodarone appears to be safe and effective in the termination of atrial fibrillation. However, extreme cases with a large left atrium and long-lasting arrhythmia need long-term therapy.
authors.affiliation: Cardiology Department, Heraklion University Hospital, Crete, Greece. cardio@med.uoc.gr
authors.forename: P E
authors.initials: PE
authors.lastname: Vardas
authors.forename: G E
authors.initials: GE
authors.lastname: Kochiadakis
authors.forename: N E
authors.initials: NE
authors.lastname: Igoumenidis
authors.forename: A M
authors.initials: AM
authors.lastname: Tsatsakis
authors.forename: E N
authors.initials: EN
authors.lastname: Simantirakis
authors.forename: G I
authors.initials: GI
authors.lastname: Chlouverakis
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage* / Q000009:adverse effects; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone